16,063 Novo Nordisk A/S $NVO Shares Bought by Hantz Financial Services Inc.

by · The Cerbat Gem

Hantz Financial Services Inc. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 13.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 133,369 shares of the company’s stock after purchasing an additional 16,063 shares during the quarter. Hantz Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $5,056,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Arrowstreet Capital Limited Partnership bought a new position in shares of Novo Nordisk A/S during the 1st quarter valued at $287,660,000. State Street Corp boosted its holdings in Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock worth $284,565,000 after purchasing an additional 32,641 shares in the last quarter. Royal Bank of Canada boosted its holdings in Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after purchasing an additional 141,376 shares in the last quarter. Envestnet Asset Management Inc. boosted its holdings in Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after purchasing an additional 71,684 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Novo Nordisk A/S by 6.7% during the first quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after buying an additional 213,443 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $41.60 on Tuesday. The firm has a fifty day simple moving average of $39.99 and a 200-day simple moving average of $43.24. The company has a current ratio of 0.84, a quick ratio of 0.64 and a debt-to-equity ratio of 0.54. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The stock has a market capitalization of $185.73 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 1.40 and a beta of 0.70.

Key Stories Impacting Novo Nordisk A/S

Investors following NVO have been watching these stories:

Analysts Set New Price Targets

Several equities analysts have weighed in on NVO shares. Cfra lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price on the stock. in a report on Tuesday, September 22nd. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. UBS Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Five research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $59.44.

Read Our Latest Report on NVO

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.

Recommended Stories

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).